Ripudaman Hundal, MD
Endocrinology, Diabetes & Metabolism · Newark, DENPI 1073591970
Payments from drug & device makers
Across 2,235 payments — averaging $165.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$141K
- Lilly USA, LLC$59K
- Boehringer Ingelheim$47K
- Amarin Pharma, Inc.$45K
- Abbott$28K
- Valeritas, Inc.$7K
- plus $42K from 52 others
What the payments were for
- Consulting fees$9,6503%
- Speaking & faculty fees$289,00278%
- Travel & lodging$28,6448%
- Food & beverage$42,45511%
- Education$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$73,594
- Ozempic$68,732
- RYBELSUS$46,837
- Vascepa$43,972
- FREESTYLE LIBRE 3$26,366
- TRULICITY$23,975
- Tresiba$17,880
- V-GO$6,525
- Pogo Automatic Blood Glucose Monitoring System$5,709
- Synthroid$4,800
- STEGLATRO$2,261
- Korlym$1,400
- CeQur Simplicity$1,371
- EVERSENSE E3 SENSOR KIT - RETAIL$450
- TZIELD$254
- SOLIQUA 100/33$221
- Omnipod$217
- MINIMED 780G$151
- GVOKE HYPOPEN$129
- EVENITY$117
How this compares
$369,857 in reported general payments places this provider in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
See all endocrinology, diabetes & metabolism providers in Delaware →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 406 | $680,042 |
| JardianceEmpagliflozin | 488 | $611,826 |
| TrulicityDulaglutide | 209 | $382,459 |
| JanuviaSitagliptin Phosphate | 151 | $186,165 |
| FarxigaDapagliflozin Propanediol | 136 | $161,770 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $109,992 |
| TymlosAbaloparatide | 25 | $93,572 |
| RybelsusSemaglutide | 63 | $91,253 |
| TradjentaLinagliptin | 74 | $90,976 |
| MounjaroTirzepatide | 72 | $90,964 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 86 | $86,051 |
| Tresiba Flextouch U-100Insulin Degludec | 106 | $85,733 |
| ProliaDenosumab | 39 | $66,662 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $61,597 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $59,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp | $141,477 | $795,858486 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $47,074 | $718,314580 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $58,604 | $488,484318 claims |
| MerckJanuvia, Janumet Xr, Janumet | $3,042 | $232,146181 claims |
| AstraZenecaFarxiga | $1,755 | $161,770136 claims |
| Radius Health, Inc.Tymlos | $1,167 | $93,57225 claims |
| AmgenProlia | $3,115 | $66,66239 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $2,897 | $22,69912 claims |
| AbbVieSynthroid | $5,985 | $21,808348 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $1,065 | $13,9201,281 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $10,82515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 30 endocrinology, diabetes & metabolism providers in Delaware.
Other endocrinology, diabetes & metabolism in Newark
- Sheetal BulchandaniNewark$4K
- Marc LaufgrabenNewark$2K
- Raafia MemonNewark$329
- Kalleen BarhamNewark$291
- Shivani VekariaNewark$207
- Valerie WestNewark$18
- Francisco PadillaSeaford$32K
- Chitra ChoudharyDover$31K
- Nira MadisiMilford$23K
- Reetu SinghLewes$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.